文献速递临床试验与 GCP基础与转化研究

急性肾损伤危重患者脑微栓塞研究:COMET-AKI随机对照试验方案

Cerebral microembolism in the critically ill with acute kidney injury (COMET-AKI trial): study protocol for a randomized controlled clinical trial.
PubMed 文献 · Trials · 2018-03-21

COMET-AKI为前瞻性随机对照试验,纳入接受连续性肾脏替代治疗(CRRT)的急性肾损伤危重患者,随机转为间歇性肾脏替代治疗(IRRT)或继续CRRT 24小时。主要终点为随机化后CRRT与IRRT测量期间平均脑微栓塞总数差异,将通过经颅多普勒、MRI及神经认知测试评估微栓塞负荷及临床后果。

要点

  • 危重AKI患者CRRT期间微栓塞负荷通过1.6-MHz机器人经颅多普勒测量大脑中动脉。
  • 随机分组比较转为IRRT与继续CRRT 24小时的脑微栓塞总数差异。
  • 同步用MRI和神经认知测试探索栓塞的形态学与临床后果。

核心结论

  • COMET-AKI试验旨在量化不同肾脏替代治疗模式下危重AKI患者到达脑循环的微栓塞负荷及其组成。

研究设计与样本

  • 前瞻性随机对照临床试验,纳入连续危重AKI患者,随机分为24小时内转为IRRT组或继续CRRT额外24小时组。
  • 评估期为2天,随访至6个月和12个月。

主要发现

  • 主要终点为随机化后CRRT与IRRT测量期间平均脑微栓塞总数差异。
  • 微栓塞在RRT回路中通过连接静脉管路的1.5-MHz超声检测器评估,脑微栓塞通过1.6-MHz机器人经颅多普勒测量大脑中动脉并自动分类固体或气体信号。

关键数值与推荐

  • 微栓塞检测采用1.5-MHz超声检测器(RRT回路)和1.6-MHz机器人经颅多普勒(大脑中动脉)。

临床怎么用

  • 结果可能帮助理解RRT模式相关的微气泡生成差异及RRT接受者的脑微栓塞负担。
  • 识别微气泡形成和分布的协变量可能促进下一代RRT回路(包括机器和/或滤器)的改进。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Microembolism is a frequent pathological event during extracorporeal renal replacement therapy (RRT). Some previous data indicate that microemboli are generated in patients who are undergoing RRT and that these may contribute to increased cerebrovascular and neurocognitive morbidity in patients with end-stage renal disease. The current trial aims to quantify the microembolic load and respective qualitative composition that effectively reaches the intracerebral circulation in critically ill patients treated with different RRT modalities for acute kidney injury (AKI). METHODS/DESIGN: The COMET-AKI trial is a prospective, randomized controlled clinical trial with a 2-day clinical assessment period and follow-up visits at 6 and 12 months. Consecutive critically ill patients with AKI on continuous renal replacement therapy (CRRT) scheduled for a switch to intermittent renal replacement therapy (IRRT) will be randomized to either switch to IRRT within the next 24 h or continued CRRT for an additional 24 h. Cerebral microembolic load will be determined at baseline, i.e., before switch (on CRRT for both groups) and on IRRT versus CRRT, whichever group they were randomized to. The primary endpoint is defined as the difference in mean total cerebral microemboli count during the measurement period on CRRT versus IRRT following randomization. Microemboli will be assessed within the RRT circuit by a 1.5-MHz ultrasound detector attached to the venous RRT tubing and cerebral microemboli will be measured in the middle cerebral artery using a 1.6-MHz robotic transcranial Doppler system with automatic classification of Doppler signals as solid or gaseous. In addition to Doppler measurements, patients will be examined by magnetic resonance imaging and neurocognitive tests to gain better understanding into the potential morphological and clinical consequences of embolization. DISCUSSION: The results of COMET-AKI may help to gain a better insight into RRT modality-associated differences regarding microbubble generation and the cerebral microembolic burden endured by RRT recipients. Furthermore, identification of covariates of microbubble formation and distribution may help to encourage the evolution of next-generation RRT circuits including machinery and/or filters. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02621749 . Registered on 3 December 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Erdoes G, Uehlinger DE, Kobel B, et al. Cerebral microembolism in the critically ill with acute kidney injury (COMET-AKI trial): study protocol for a randomized controlled clinical trial. Trials. 2018. PMID: 29562937. doi:10.1186/s13063-018-2561-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。